Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT ID: NCT07101094
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2025-09-22
2029-05-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
NCT03697252
An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients
NCT06923891
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
NCT05919823
A Study to Evaluate the Effect of KarXT on Urological Safety
NCT07221877
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
NCT04659161
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants receiving xanomeline and trospium chloride (X/T) therapy
xanomeline and trospium chloride (X/T) therapy
According to the product label
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
xanomeline and trospium chloride (X/T) therapy
According to the product label
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a confirmed diagnosis of schizophrenia before index date.
* Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy.
* Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines.
* Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish).
* English or Spanish speaking.
Exclusion Criteria
* Evidence of use of XT prior to time of eligibility screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0009
Orange, California, United States
Local Institution - 0010
San Jose, California, United States
Local Institution - 0003
Evanston, Illinois, United States
Local Institution - 0007
Baltimore, Maryland, United States
Local Institution - 0004
Catonsville, Maryland, United States
Local Institution - 0008
Belmont, Massachusetts, United States
Local Institution - 0002
Boston, Massachusetts, United States
Mayflower Clinical
South Dartmouth, Massachusetts, United States
Omaha Insomnia and Psychiatric Services
Omaha, Nebraska, United States
Hackensack Meridian Health - Carrier Clinic
Belle Mead, New Jersey, United States
Local Institution - 0015
New York, New York, United States
Local Institution - 0016
Kinston, North Carolina, United States
Local Institution - 0014
Westlake, Ohio, United States
Continuum Health Providers
Fort Mill, South Carolina, United States
Local Institution - 0012
El Paso, Texas, United States
Local Institution - 0013
Longview, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Study Connect Contact Center www.BMSStudyConnect.com
Role: CONTACT
First line of the email MUST contain NCT # and Site #.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site 0009
Role: primary
Site 0010
Role: primary
Site 0003
Role: primary
Site 0007
Role: primary
Site 0008
Role: primary
Site 0002
Role: primary
Simon Desjardins, Site 0011
Role: primary
Vithya Selvaraj, Site 0005
Role: primary
Stacy Doumas, Site 0001
Role: primary
Site 0015
Role: primary
Site 0016
Role: primary
Site 0014
Role: primary
Brian Mika, Site 0006
Role: primary
Site 0012
Role: primary
Site 0013
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CN012-0066
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.